Toxicity of immunotherapy with interleukin-2 and lymphokine-activated killer cells.
Immunotherapy with IL-2 represents a major breakthrough in the management of renal cell carcinoma and malignant melanoma. At present, the toxicity of most IL-2 regimens is severe and prohibitive for clinicians not intimately familiar with the myriad of side effects associated with its use. The elucidation of the mechanism by which the lymphokine induces tumor regression, the vascular leak syndrome and other side effects will permit IL-2 to be used more safely and effectively.
Mier
J W
JW
Department of Medicine, New England Medical Center, Boston, Mass.
Aronson
F R
FR
Numerof
R P
RP
Vachino
G
G
Atkins
M B
MB
D001685:Biological Factors / Q000096:biosynthesis; D002986:Clinical Trials as Topic; D016207:Cytokines; D003875:Drug Eruptions / Q000209:etiology; D004417:Dyspnea / Q000139:chemically induced; D004487:Edema / Q000139:chemically induced; D004730:Endothelium, Vascular / Q000187:drug effects; D005221:Fatigue / Q000139:chemically induced; D005334:Fever / Q000139:chemically induced; D005767:Gastrointestinal Diseases / Q000139:chemically induced; D006331:Heart Diseases / Q000139:chemically induced; D006402:Hematologic Diseases / Q000139:chemically induced; D006801:Humans; D006932:Hyperbilirubinemia / Q000209:etiology; D007022:Hypotension / Q000139:chemically induced; D007037:Hypothyroidism / Q000139:chemically induced; D007116:Immunization, Passive / Q000009:adverse effects*; D007376:Interleukin-2 / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D007674:Kidney Diseases / Q000139:chemically induced; D007694:Killer Cells, Natural / Q000276:immunology / Q000637:transplantation*; D009369:Neoplasms / Q000150:complications / Q000628:therapy*; D009422:Nervous System Diseases / Q000139:chemically induced
D001685:Biological Factors; D016207:Cytokines; D007376:Interleukin-2